SBIR/STTR Research Award

Non-coating anti-microbial, anti-host protein deposition, anti-inflammatory urinary catheter

Award identifier 14bc07dc4084537facdbeb61865a4aacebbcb10cedac7502d12ed3a7d3a7f22dAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$325,001

Program and phase

SBIR · Phase I

Award year

2023

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Halomine Inc. dba AvantGuard
Proposal award date
2023-06-05
Contract end date
2024-05-31
UEI
FT1LJN4UPKJ3
Solicitation number
PA22-176
Topic code
400

Research abstract

Abstract: Catheter-associated urinary tract infection (CAUTI) is the most common type of healthcare-associated infection, however currently there is no effective technology to address the problem. Antimicrobial (anti-biofilm) functionality on the catheter surface is an important field that has gained a lot of attention; however, commercial applications are limited due to a lack of infection control outcomes (silver-hydrogel coating) or irritation/discomfort (nitrofural) in clinical trials. Recent research has now shown that biofilm formation is caused by protein deposition which will also cause inflammation and immunoreaction. Therefore, the next generation technology needs both antimicrobial functionalities along with anti-immunoreaction capabilities to produce a compound effect for infection control. Our company invented a new category of polymer additive product (HaloAddTM) that can be cost-effectively blended into existing silicon rubber resins to produce silicone urinary catheters that can provide multiple functions such as antimicrobial, anti-protein adhesion and anti-inflammation. This phase I effort is geared towards answering some basic feasibility, efficacy, and safety questions about this approach using both in vitro and in vivo testing methods. We propose three specific aims: 1) optimize polymer synthesis and blending parameters to develop HaloAdd-blended silicone rubber formulas with maximum antimicrobial and anti-fouling efficacy; 2) determine uropathogen attachment prevention, biocompatibility, and stability of HaloAdd-blended silicone tubes; 3) demonstrate in vivo that HaloAdd catheter provides measurable anti-inflammation and anti-biofilm outcomes in a mouse infection model. Success with this phase I effort will lay the groundwork for FDA clearance for human trials.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

13 SBIR/STTR records share this UEI (2020–2025). Reported award amounts total $6,629,244. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, National Science Foundation, Department of Agriculture, Department of Defense

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.